CTD Dossier Preparation: A Step by Step Guide for Emerging Markets

The Common Technical Document, or CTD, is the internationally agreed format for submitting information about a medicine to regulators. Developed through the International Council for Harmonisation, it has become the common language of drug registration. Many emerging markets now accept CTD or a regional variant such as ACTD, which means a strong master dossier can be adapted for several countries and save significant time and cost.

Yet dossier preparation remains one of the most common bottlenecks in export growth. Missing data, inconsistent numbers and unclear justifications lead to query letters that can add months to approval timelines. This guide walks through each stage of preparing a CTD that regulators can approve efficiently.

Understand the Five Modules

• Module 1: Regional administrative information, application forms, certificates and labelling. This module is country specific.
• Module 2: Summaries and overviews of quality, non clinical and clinical data, including the Quality Overall Summary.
• Module 3: Quality information covering the drug substance and drug product.
• Module 4: Non clinical study reports, often referenced from literature for well established generics.
• Module 5: Clinical study reports, including bioequivalence data for generics.

Plan Before You Compile

Most delays come from missing data, not poor writing. Start with a checklist for each target country and confirm which stability zones, bioequivalence requirements, reference products and labelling rules apply. Then map every required document against what already exists and identify gaps early.

1. List all target countries and their specific dossier requirements.
2. Confirm the reference product accepted by each regulator.
3. Check that stability data matches the climatic zone of each market.
4. Collect current GMP certificates, COPPs and licences for Module 1.
5. Assign owners and deadlines for every missing document.

Build a Strong Module 3

For generic products, Module 3 carries the most weight. It should tell a clear story from raw materials to finished product.

Drug Substance (3.2.S)

Include the API manufacturer details, specifications, certificates of analysis and, where available, the open part of the Drug Master File or a Certificate of Suitability. Make sure your own API testing specification aligns with the supplier specification and pharmacopoeial requirements.

Drug Product (3.2.P)

Describe the composition, pharmaceutical development, manufacturing process with process controls, excipient specifications, finished product specifications with justification, analytical method validation, batch analyses, container closure system and stability data.

Consistency is everything. A batch size or specification that differs between two sections is one of the most common reasons for regulator queries.

Write a Clear Quality Overall Summary

The Quality Overall Summary in Module 2 is often the first section reviewers read. It should summarise Module 3 accurately, highlight critical quality attributes and explain key development decisions. Avoid copying Module 3 word for word; instead, give reviewers a concise map of where to find evidence.

Handle Bioequivalence Requirements

For oral solid generics, many regulators expect a bioequivalence study against their accepted reference product. Some authorities accept studies performed against a reference product from another stringent market, while others require the locally marketed reference. Where biowaivers are possible, for example for certain BCS class products or proportional strengths, prepare a well argued justification supported by comparative dissolution profiles.

Perform a Rigorous Internal Review

Before submission, run a structured quality check:

• Cross check numbers such as batch sizes, strengths and specifications across modules
• Verify that every referenced document is included and correctly labelled
• Confirm signatures, dates and certificate validity
• Check bookmarks, hyperlinks and file naming for electronic submissions
• Review Module 1 against the latest country checklist

Submit and Manage Queries

1. Submit in the required format, whether paper, CTD PDF or eCTD.
2. Track review timelines and keep a register of all correspondence.
3. Respond to queries quickly, completely and with supporting data.
4. Update the master dossier with every accepted change for future submissions.

Maintain the Dossier After Approval

Registration is not the end of the journey. Changes to the manufacturing site, process, specifications or packaging require variation filings, and registrations must be renewed periodically. Keep a lifecycle tracker for every product and country so that variations and renewals are filed on time.

Country Specific Adaptations

Even when a regulator accepts the CTD format, national requirements differ. Some countries require local stability data or specific climatic zone conditions, others ask for samples with the application, notarised or legalised certificates, or product specific forms. Many require labelling and leaflets in the local language and format. Maintain a country requirement sheet for each market and update it whenever guidance changes, so that Module 1 and any additional data are right first time.

Where regional work sharing or reliance procedures exist, such as joint assessments or abridged pathways based on approvals by reference authorities, evaluate whether your product qualifies. These routes can shorten timelines significantly.

Working With API Suppliers

Dossier quality depends heavily on the information your API supplier can provide. Before selecting a supplier, confirm that they can share the open part of a Drug Master File or a Certificate of Suitability, a letter of access where needed, impurity profiles, stability data and GMP evidence. Agree in writing how they will notify you of changes to their process or site, because such changes may require variations to your registrations. Switching API suppliers after registration is usually possible but requires comparative data and regulatory approval, so choose carefully at the start.

Frequently Missed Items

• Justification of specifications, especially impurity limits
• Complete method validation reports rather than summaries
• Batch analysis data for the batches used in stability and bioequivalence
• Container closure details, including food grade or pharmacopoeial compliance
• Signed and dated declarations required in Module 1

Adding these to your internal checklist prevents many of the queries regulators raise most often.

Finally, keep an electronic master copy of every dossier with version control. When a regulator asks a question two years after submission, being able to find exactly what was filed, and when, saves time and prevents inconsistent answers across markets.

Zanax Healthcare prepares, reviews and publishes CTD and ACTD dossiers for emerging and regulated markets and supports clients through query responses and lifecycle management.